A virus-like particle vaccine candidate for Crimean-Congo haemorrhagic fever has shown experimental rapid onset and durable ...

Evercore 8th Annual Healthcare Conference December 3, 2025 2:35 PM ESTCompany ParticipantsSteven Harr - President, CEO ...

People infected with HIV must take antiretroviral drugs for life. But promising trials using engineered antibodies suggest ...

This report provides useful evidence that EABR mRNA is at least as effective as standard S mRNA vaccines for the SARS-CoV-2 booster vaccine. Although the methodology and the experimental approaches ...

People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus ...

为评估单剂HPV疫苗的长期免疫保护潜力，研究人员在DoRIS随机对照试验中，系统比较了Cervarix?和Gardasil?9疫苗1/2/3剂方案诱导的记忆B细胞（MBCs）反应。结果显示单剂疫苗可诱导持久的MBCs反应至36个月，且MBCs频率与抗体水平呈正相关，为单剂HPV疫苗接种策略提供了重要的免疫学依据。

Scientists create a vaccine that shields against Crimean-Congo hemorrhagic fever within days and protects for over a year.

University of Queensland researchers visualized yellow fever virus particles at near-atomic detail, uncovering major ...

The global oncolytic virus CDMO services market size is valued at USD 419.51 million in 2025 and is predicted to hit around ...

Frustrated cancer patients worry they may have been exposed to unknown carcinogens. Researchers are on the hunt.

A new vaccine targeting the deadly Crimean-Congo hemorrhagic fever virus shows rapid protection in mice, working within days ...

Ancient viral fossils buried in our DNA are offering fresh clues about how today’s respiratory pathogens infect and spread.